Location History:
- Musashino-shi, Tokyo, JP (2010)
- Musashino, JP (2010 - 2012)
- Tokyo, JP (2010 - 2020)
- Bunkyo-ku, JP (2015 - 2021)
Company Filing History:
16 out of 1,287 
13 out of 950 
12 out of 26 
Years Active: 2010-2021
Title: The Innovations of Hiroyuki Aburatani in Cancer Research
Introduction
Hiroyuki Aburatani, a distinguished inventor based in Tokyo, Japan, holds an impressive portfolio of 27 patents. His work primarily centers around advancements in cancer diagnosis and treatment, reflecting his commitment to improving patient outcomes through innovative biotechnological solutions.
Latest Patents
Among his latest contributions is the patent for an Anti-DLL3 antibody, designed to bind specifically to the DLL3 protein. This innovative antibody recognizes a region from amino acids 216 to 492 in human DLL3, aligning with the amino acid sequence set forth in SEQ ID NO: 1. The invention also encompasses a pharmaceutical composition, such as an anticancer agent, which includes this antibody as an active ingredient. Additionally, it outlines a method for diagnosing cancer and a corresponding diagnostic drug utilizing the antibody.
Another notable patent involves the diagnosis and treatment of cancer using anti-desmoglein-3 antibodies. This invention presents methods for detecting DSG3 protein, which is crucial for diagnosing lung cancer, given the high frequency of DSG3 expression at both gene and protein levels in affected patients. The methods disclosed can utilize antibodies that specifically recognize DSG3 proteins, and the patent also describes pharmaceutical compositions, including cell growth inhibitors and anticancer agents that incorporate DSG3-binding antibodies to suppress the proliferation of DSG3-expressing cells.
Career Highlights
Hiroyuki Aburatani has contributed significantly to the field through his affiliations with prestigious institutions, such as The University of Tokyo and Chugai Seiyaku Kabushiki Kaisha. His work in these organizations has fostered innovations in cancer research, establishing him as a key figure in the development of novel therapeutic and diagnostic approaches.
Collaborations
Throughout his career, Aburatani has collaborated with esteemed colleagues, including Shumpei Ishikawa and Hirotaka Ito. These partnerships have not only enhanced his research capabilities but have also contributed to the success of numerous projects aimed at tackling critical health challenges, particularly in oncology.
Conclusion
Hiroyuki Aburatani's contributions to cancer research through his patents exemplify the profound impact of innovation in biotechnology. His work continues to pave the way for new diagnostic and therapeutic strategies that hold promise for improving the lives of cancer patients. As a leading inventor in his field, Aburatani remains a vital asset to ongoing research and development efforts.